Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 27, 2015

View Archived Issues

Almirall describes novel CRAC channel inhibitors

Discovery, structure of AG-221 presented by Agios Pharmaceuticals

Stemcell Technologies licenses research assets from iPS Academia Japan

RedHill Biopharma hires Recipharm to manufacture phase III candidate

Amgen gives details on discovery of AMG-337

MSI Methylation announces last patient treated in phase II trial of ademetionine in MDD

Oncoceutics announces start of expansion phase in first-in-human ONC-201 trial

GSK poised to begin first-in-human trial of GSK-3174998

Janssen Pharmaceutical presents FFAR4 agonists

Edoxaban endorsed by NICE

Advaxis enters into licensing agreement with Knight Therapeutics for Canada

Bayer Schering Pharma discloses BRD4 inhibitors

RespiVert and Topivert Pharma patent anti-inflammatory kinase inhibitors

Tissue Therapies partners with the Queensland University of Technology on research

Incyte divulges KDM1A inhibitors

Principia Biopharma presents FGFR inhibitors

Alvogen to acquire product portfolio from Pfizer for the U.S.

Global trial of palbociclib launched for patients with hormone receptor-positive early breast cancer

Audentes Therapeutics' AT-001 receives orphan drug designation

Syndax and Genentech to conduct phase Ib/II trial combining entinostat and atezolizumab

Novel nanoparticle-based Epstein-Barr virus vaccine elicits potent antibody responses

Valneva updates on 2015 EB66 licensing agreements

Novo Nordisk begins phase IIIa development of oral semaglutide

Daratumumab gains third FDA orphan drug designation

Strategies focused on the HA stem advance universal influenza vaccine development

Allied-Bristol licenses antibody-recruiting molecule technology from Yale

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan. 13, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 13, 2025
Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal
BioWorld
The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire...
Proteomics study explores how protein changes influence disease
BioWorld Science
Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to...
Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance
BioWorld
Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.